Skip to content

Feasibility & Characterization of Project: EVO Monitor Cognitive Measurements

A Study to Assess the Feasibility of and to Characterize Project: EVO Monitor Cognitive Function Measurements When Played Daily, Weekly, or Multiple Times Per Day in Adults 40-55 Years Old

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02792296
Enrollment
71
Registered
2016-06-07
Start date
2016-06-30
Completion date
2016-11-30
Last updated
2016-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

This is an open-label study in adults to assess at-home Project: EVO Monitor measurements over repeat play cycles. The study has three arms:playing multiple times per day, once daily, and once weekly for 4 to 8 weeks.

Detailed description

This is an open-label study in adults ages 40 to 55 to assess Project: EVO Monitor measurements over repeat play cycles. The study has three arms: adults playing multiple times per day, adults playing once daily, and adults playing once weekly. The investigators plan to evaluate 76 participants (N = 30 in the daily and weekly arms, and N=16 in the multiple times per day arm) in two sites over a 4 to 8 week study period. The study period includes 2 in-clinic sessions and scheduled, at-home game play of the short (less than 7 minutes) Project: EVO Monitor.

Interventions

OTHERProject: EVO Monitor

Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.

Sponsors

Akili Interactive Labs, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Age: 40-55 at the time of informed consent * Ability to follow written and verbal instructions (English). * Male and Female (Gender-matched). * Ability to comply with all the testing and requirements.

Exclusion criteria

* Current, controlled (requiring a restricted medication) or uncontrolled, self-reported psychiatric diagnosis with significant symptoms such as post-traumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, attention deficit disorder, autism spectrum disorder, or other symptomatic manifestations that in the opinion of the Investigator that may confound study data/assessments. * Current self-reported community diagnosis of cognitive ailments such as dementia, Alzheimer's disease, stroke, traumatic brain injury, or other diseases that in the opinion of the Investigator that may confound study data/assessments. * Current diagnosis of severe learning disorder, dyslexia, or dyscalculia. * Current subjective complaints of inattention or memory loss. * Current use of psychotropic medication, prescription or otherwise. * Currently undergoing psychotherapy, behavioral therapy, or occupational therapy. * Motor condition that prevents game playing, as observed by investigator. * Impaired visual acuity, as defined by difficulty reading the informed consent even with corrective lenses. * Recent history (within the past 6 months) of suspected substance abuse or dependence. * History of seizures (exclusive of febrile seizures), a tic disorder, significant tics, a current diagnosis of Tourette's Disorder. * Taken part in a clinical trial within 30 days prior to screening. * Diagnosis of color blindness. * Regular use of psychoactive drugs that in the opinion of the Investigator may confound study data/assessments * Any other medical condition that in the opinion of the investigator may confound study data/assessments.

Design outcomes

Primary

MeasureTime frame
Feasibility of at-home use as measured by percent of completed assigned sessions4 to 8 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026